Clinical Trials Directory

Trials / Completed

CompletedNCT03405688

Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
173 (actual)
Sponsor
Hanane EL KENZ · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Bearers of the sickle cell allele (S) are currently eligible for blood donations in Belgium. As blood donors are not tested for this allele, their heterozygous status is unknown. However, guidelines recommend to transfuse sickle cell patients with blood that is negative for the 'S' hemoglobin. To the investigator's knowledge, no study has been conducted to evaluate the impact of transfusion with blood originating from heterozygous donors on the transfusion performance and the improvement of clinical status of the sickle cell disease patients.

Conditions

Interventions

TypeNameDescription
PROCEDUREBlood samplingExtra blood samples taken for laboratory analysis

Timeline

Start date
2018-02-13
Primary completion
2020-08-03
Completion
2020-08-03
First posted
2018-01-23
Last updated
2021-01-28

Locations

2 sites across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03405688. Inclusion in this directory is not an endorsement.

Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors (NCT03405688) · Clinical Trials Directory